Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-398 + Nivolumab in KRAS-mutated NSCLC
NCT05375084Phase 1Terminated
- Sponsor
- BridgeBio Pharma
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986466 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by BridgeBio Pharma. Primary endpoints: Safety and Tolerability at 28 days and Objective Response Rate at 28 days. Started Oct 2022; status: terminated.
02
Drugs
BMS-986466
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05375084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375084.